Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Filing Imminent As Mycovia’s Antifungal Prevents Recurrent Vulvovaginal Candidiasis

Private Company Is Preparing For Commercialization, Talking To Partners

Executive Summary

Oteseconazole prevented recurrent VVC in two Phase III studies but Phase III data in acute treatment of VVC episodes in women with RVVC, also due this month, are needed to file for US FDA approval in the first half of 2021.

You may also be interested in...



Vaginal Yeast Infections Are A Bright Spot For Anti-Infective Development

Working with US FDA was key to developing clinical trials in the absence of regulatory precedents in recurrent vulvovaginal candidiasis, Scynexis VP tells the Pink Sheet; exposure profiles drove different trial designs for Scynexis’ Brexafemme and Mycovia’s just-launched Vivjoa.

Scynexis Data Show Brexafemme Prevents VVC Recurrence

Phase III data showed that the first-in-class oral antifungal can prevent recurrence of vaginal yeast infections, a potentially valuable label addition to the current indication for acute treatment.

Scynexis Prepares To Launch Brexafemme In Vaginal Yeast Infections, Priced At $475

The first-in-class, novel antifungal for vaginal yeast infections will enter a genericized market, but also one with strong demand for better therapeutic options.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC143462

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel